ArticlePloS one2025
In vitro experiments and network pharmacology-based investigation of the molecular mechanism of neferine in the treatment of gastric cancer.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molegro Data Modeller to Estimate CDK6 Inhibition.Methods in molecular biology (Clifton, N.J.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Background Gastric cancer is the world's leading tumor disease in terms of morbidity and mortality and is currently treated clinically with a comprehensive approach based on surgery. Studies have demonstrated the antitumor effects of neferine, but the anti-cancer mechanism for gastric cancer is not yet clear. Methods The Pubchem and Swiss TargetPrediction databases were searched to retrieve the targets of action of neferine. Meanwhile, relevant gene expression data were downloaded by means of the Gene Expression Omnibus(GEO) database to screen for differential genes and build a drug-disease network. The selected genes were analysed by bioinformatics analysis. Finally, gastric cancer treatment potential of neferine was determined through molecular docking. The molecular mechanism of neferine in the treatment of gastric cancer was verified by CCK8 assay, monoclonal assay, apoptotic and cycle assay, qRT-PCR and Western Blot. Results The results of network pharmacological analyses illustrate that the core genes are closely related to apoptosis, cell cycle, and cell proliferation. Through molecular docking, it was confirmed that neferine were closely related to key proteins. The results of in vitro experiments indicated that neferine could significantly inhibit the viability of gastric cancer cells, induce apoptosis of gastric cancer cells, and block the cell cycle of gastric cancer cells in the G0/G1 phase. Conclusion In summary, neferine inhibited the proliferation of gastric cancer cells through the CDK4/CDK6/CyclinD1 complex. This study provides a theoretical basis for the treatment of gastric cancer with neferine and an idea for the development of neferine for gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.